Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer

Identification of activating mutations in non-small cell lung cancers (NSCLC) has been a focus in recent years. This led to successful evidence of using tyrosine kinase inhibitors (TKIs) over the standard platinum doublet based chemotherapy as the first line treatment in the metastatic setting.The r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramshankar, Vijayalakshmi, Yegnaswamy, Subha, P, Kumarasamy, Arvind, Krishnamurthy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2014
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248349/
https://www.ncbi.nlm.nih.gov/pubmed/25489176
http://dx.doi.org/10.6026/97320630010658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248349/
https://www.ncbi.nlm.nih.gov/pubmed/25489176
http://dx.doi.org/10.6026/97320630010658

Ejemplares similares